Did Johnson & Johnson beat expectations and raise guidance?

The company raised its 2026 outlook. Reported sales guidance now stands at $100.8B to $101.4B (midpoint $101.1B, up from a $100.8B midpoint), and adjusted EPS guidance rose to $11.60 to $11.75 (midpoint $11.68, up $0.13). The release does not include consensus comparisons, so the beat magnitude relative to Street expectations cannot be determined from this filing alone.

Why did GAAP EPS decline while adjusted EPS grew?

GAAP diluted EPS fell 0.9% to $2.27 because of higher special items, including $267 million of litigation-related charges, $276 million of restructuring-related costs, $258 million of Orthopaedics separation costs and $80 million of acquisition and integration costs, along with higher other expense and a higher effective tax rate (18.0% versus 14.7%). Adjusted EPS excludes these items and intangible amortization ($1.245 billion pre-tax), which is why it rose 4.7% to $2.90.

How significant is the STELARA decline for the investment case?

STELARA sales fell 55.2% to $740 million in Q2, reducing Innovative Medicine growth by about 760 basis points. This is a known biosimilar erosion dynamic, and the company's growth is increasingly reliant on DARZALEX, TREMFYA, CARVYKTI and other newer products to offset it. Investors should monitor whether these launches can continue to offset the continuing STELARA decline in the second half of 2026.

What is the status of the Orthopaedics separation and what does it cost?

The filing references a planned separation of the Orthopaedics business and records $258 million of related pre-tax costs in Q2 2026 ($377 million year to date). The separation is a significant near-term cost driver that is excluded from adjusted results, so investors should weigh the GAAP impact and watch for further separation disclosures.

Is free cash flow reliable, and what should investors know about the metric?

Free cash flow of approximately $8.7 billion is a non-GAAP measure defined as operating cash flow less capital expenditures. The company has stated that the most directly comparable GAAP measure, cash flow from operations, will appear in subsequent SEC filings, and the figure is described as estimated as of July 15, 2026, so it may be revised when the 10-Q is filed.

JNJ 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 15, 2026. Cited figures are marked; the original filing is the authoritative source.

Johnson & Johnson reported second-quarter 2026 results on July 15, 2026, with reported sales of $25.3 billion^a, up 6.6% year over year (5.6% operational, 5.7% adjusted operational growth).

Growth was led by Innovative Medicine, where sales rose 7.8% reported, driven by DARZALEX, CARVYKTI, TREMFYA, TECVAYLI and CAPLYTA, partly offset by a steep decline in STELARA (down 55% reported) following biosimilar erosion. MedTech sales rose 4.5% reported, with the strongest contributions from wound closure, biosurgery, electrophysiology, Shockwave and contact lenses. GAAP EPS was $2.27^b, down 0.9%, as GAAP net earnings were roughly flat at $5.5 billion, weighed down by higher SG&A (up 9.2%), higher other expense (including litigation and Orthopaedics separation costs) and a higher effective tax rate of 18.0%.

Adjusted EPS rose 4.7% to $2.90^c, and free cash flow was estimated at roughly $8.7 billion year to date versus $6.2 billion a year earlier. Management raised full-year 2026 guidance. Estimated reported sales are now $100.8B to $101.4B (midpoint $101.1B, up 7.3%, previously $100.8B midpoint), and adjusted EPS is $11.60 to $11.75 (midpoint $11.68, up $0.13).

Adjusted operational EPS guidance rose $0.18^d to a midpoint of $11.58. The company is also targeting more than $100 billion in annual revenue for the first time in its history. Note that the guidance midpoint for reported sales ($101.1B) is above the $100B target, and the raised guidance reflects a modest currency tailwind assumption embedded in the euro rate ($1.15 versus $1.17 previously).

Key watch items include the STELARA erosion, a new supply chain restructuring program (estimated $650 to $750 million through 2029, with $200 million recorded in Q2), the ongoing Orthopaedics separation (which generated $258 million of pre-tax costs in the quarter), and continued litigation exposure. The disclosure is an Item 2.02 filing furnishing the earnings release and supplementary data; the 8-K itself contains no new financial statements beyond what is attached as exhibits.

02—Key points

Key Highlights

Q2 2026 reported sales of $25.3B, up 6.6% (5.6% operational, 5.7% adjusted operational), with U.S. growth of 7.3% and International growth of 5.7%.
GAAP diluted EPS of $2.27 (down 0.9%) and adjusted EPS of $2.90 (up 4.7%); GAAP net earnings were essentially flat at $5.53B versus $5.54B a year earlier.
Full-year 2026 guidance raised: reported sales $100.8B to $101.4B (7.3% growth at midpoint) and adjusted EPS $11.60 to $11.75 (midpoint $11.68, up $0.13).
Innovative Medicine grew 7.8% reported, led by DARZALEX (+18.9%), TREMFYA (+72.5%), CARVYKTI (+49.4%), and CAPLYTA, partly offset by STELARA (down 55.2%) as biosimilar competition took hold.
MedTech grew 4.5% reported, with Shockwave (+14.6%), Electrophysiology (+4.4%), Vision (+6.0%) and Orthopaedics (+4.9%) contributing, while Surgery grew 3.9%.
A new supply chain restructuring program was launched with estimated costs of $650 to $750 million through 2029, of which $200 million was recognized in Q2 2026, primarily asset impairments.
Free cash flow is estimated at about $8.7B year to date, up from $6.2B in the prior-year period, a strong cash generation signal ahead of the Orthopaedics separation.

03—Questions

Frequently Asked Questions

Did Johnson & Johnson beat expectations and raise guidance?
The company raised its 2026 outlook. Reported sales guidance now stands at $100.8B to $101.4B (midpoint $101.1B, up from a $100.8B midpoint), and adjusted EPS guidance rose to $11.60 to $11.75 (midpoint $11.68, up $0.13). The release does not include consensus comparisons, so the beat magnitude relative to Street expectations cannot be determined from this filing alone.
Why did GAAP EPS decline while adjusted EPS grew?
GAAP diluted EPS fell 0.9% to $2.27 because of higher special items, including $267 million of litigation-related charges, $276 million of restructuring-related costs, $258 million of Orthopaedics separation costs and $80 million of acquisition and integration costs, along with higher other expense and a higher effective tax rate (18.0% versus 14.7%). Adjusted EPS excludes these items and intangible amortization ($1.245 billion pre-tax), which is why it rose 4.7% to $2.90.
How significant is the STELARA decline for the investment case?
STELARA sales fell 55.2% to $740 million in Q2, reducing Innovative Medicine growth by about 760 basis points. This is a known biosimilar erosion dynamic, and the company's growth is increasingly reliant on DARZALEX, TREMFYA, CARVYKTI and other newer products to offset it. Investors should monitor whether these launches can continue to offset the continuing STELARA decline in the second half of 2026.
What is the status of the Orthopaedics separation and what does it cost?
The filing references a planned separation of the Orthopaedics business and records $258 million of related pre-tax costs in Q2 2026 ($377 million year to date). The separation is a significant near-term cost driver that is excluded from adjusted results, so investors should weigh the GAAP impact and watch for further separation disclosures.
Is free cash flow reliable, and what should investors know about the metric?
Free cash flow of approximately $8.7 billion is a non-GAAP measure defined as operating cash flow less capital expenditures. The company has stated that the most directly comparable GAAP measure, cash flow from operations, will appear in subsequent SEC filings, and the figure is described as estimated as of July 15, 2026, so it may be revised when the 10-Q is filed.

04—Continue

← View all 8-K filings